The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with ¹⁷⁷Lu DOTATATE (LuTate).

ABSTRACT: Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with respect to response by ⁶⁸ Ga DOTATATE (GaTate) PET/CT molecular imaging tumour volume of SSR (MITV_SSR) change and RECIST 1.1, and overall survival (OS).

Methods

Patients with gastro-entero-pancreatic (GEP) NEN who received LuTate followed by quantitative SPECT/CT (Q-SPECT/CT) the next day (Jul 2010 to Jan 2019) were retrospectively reviewed. Single time-point (STP) lesional dosimetry was performed for each cycle using population-based pharmacokinetic modelling. MITV_SSR and RECIST 1.1 were measured at 3-months post PRRT.

SUBMITTER: Alipour R 

PROVIDER: S-EPMC10382388 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature